학술논문
Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals.
Document Type
Academic Journal
Author
Méndez-Sánchez N; Unit Liver Research, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico.; Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico.; Coronel-Castillo CE; Internal Medicine Section, Central Military Hospital, Mexico City 11649, Mexico.; Ramírez-Mejía MM; Unit Liver Research, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico.; Plan of Combined Studies in Medicine (PECEM MD/PhD), Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico.
Source
Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101596317 Publication Model: Electronic Cited Medium: Print ISSN: 2076-0817 (Print) Linking ISSN: 20760817 NLM ISO Abbreviation: Pathogens Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2076-0817
Abstract
Chronic hepatitis C virus infection is an important cause of liver cirrhosis, hepatocellular carcinoma and death. Furthermore, it is estimated that about 40-70% of patients develop non-hepatic alterations in the course of chronic infection. Such manifestations can be immune-related conditions, lymphoproliferative disorders and metabolic alterations with serious adverse events in the short and long term. The introduction of new Direct-Acting Antivirals has shown promising results, with current evidence indicating an improvement and remission of these conditions after a sustained virological response.